Close Menu

E5103

Despite pleas of breast cancer advocates to maintain access to Avastin using gene markers to identify those most likely to benefit, there is little evidence to suggest that the drug company or regulatory experts are considering this strategy.

NCI has outlined changes to its IP policies for collaborative research agreements that would essentially provide industry collaborators with first-option commercial licensing rights for IP arising from studies that make use of pharma companies' proprietary drugs, or samples from patients treated with those drugs.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.